Clinical Treatment Studies

Schizophrenia Trial

A multicenter, open-label study to assess hospitalization rates in adult subjects with schizophrenia treated prospectively for 6 months with Aripiprazole IM Depot compared with 6-month retrospective treatment with oral antipsychotics in a naturalistic community setting in the United States.

Participants must:

  • be between the ages of 18 and 65 years
  • have diagnosis of schizophrenia
  • have 1 inpatient psychiatric hospitalization within past 2 years
  • have no non-psychiatric hospitalization within past 4 weeks
  • currently be on oral antipsychotic treatment for past 7 months

Participants cannot:

  • have a history of head injury or other neurological disorder
  • have a current or past history of drug dependence
  • have significant extra pyramidal symptoms (tremors, akathisia) or tardive dyskinesia 
Roche Depression Trial

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Protocol # BP25712

Participants must:

  • be between the ages of 18 and 65 years
  • have a diagnosis of depression
  • have an inadequate response to current antidepressant treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI)

Participants cannot:

  • currently be receiving treatment with a combination of 3 or more antidepressants
  • have alcohol and/or substance abuse/dependence during the last 6 months
  • have a significant ongoing use of high doses of barbiturates, benzodiazepines or other anxiolytic drugs
Forest Depression Trial

A double-blind, placebo-controlled study of cariprazine as adjunctive therapy in major depressive disorder

Participants must:

  • be between the ages of 18 to 65 years
  • have a diagnosis of depression
  • have ongoing inadequate response to bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, sertraline, venlafaxine, or vilazodone

Participants cannot:

  • have any anticonvulsant/mood stabilizer, anxiolytic, benzodiazepine or other anti-depressant agent within one week of entering the study
  • have alcohol and/or substance abuse/dependence during the last 6 months
  • have a positive hepatitis C antibody on screening
Alcohol Dependence Trial

This study uses psychotherapy in combination with an experimental mind-altering medication, administered in a clinical setting, to see if this approach promotes recovery from problems with alcohol. Medical and psychiatric evaluations as well as treatment interventions are conducted free of charge.

Participants must:

  • be between the ages of 25 and 65
  • be alcohol dependent
  • be concerned about their drinking
  • have at least 4 heavy drinking days in the past 30 days